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Abstract
Some ecological studies have shown that areas with higher use of cannabis
may have lower opioid use and fewer opioid-related problems. Newer studies
are questioning this finding. Few individually based studies have been per-
formed. Using data from the Norwegian Prescription Database, this study
investigated the individual level effect of prescribed cannabis extract
(Sativex®) in prescription opioid users on their opioid use in the following
year. Looking at all those filling a prescription for Sativex®, opioid use was
only marginally lowered in the follow-up period. Some Sativex® users, how-
ever, filled more prescriptions for Sativex® and were able to reduce their opioid
use substantially. Further studies are needed to elucidate more details on these
patients, so as to know who can benefit from such cannabis-based extracts in
reducing their opioid use.
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1 | INTRODUCTION
Opioids are effective for treating acute pain, but caution
should be observed when using these drugs for chronic
conditions because of the problem of tolerance
development,1,2 prescription drug abuse and opioid
dependence.3 The United States have seen a sharp
increase in the use of prescription opioids during recent
decades followed by a dramatic increase in the use of
heroin,4 a high number of overdose deaths5 and even in
the number of suicides.6
Cannabis is used for recreational purposes through-
out the world and is the most commonly used illegal
drug.7 Although regulated by international treaties on
narcotics trade, it has been legalized in several states in
the United States and in some other countries.8 We have
also seen extensive use of medical cannabis drug, with
easy access for many groups.9
We have seen increasing research on the medical use
of cannabis for several different maladies.10 Many of the
suggested indications are currently speculative, but a
modest effect on neuropathic pain seems to be a well-
documented indication.11–14 However, these reviews have
been criticized for their quality, and more rigorous
reviews have been requested.15–17
It has been debated whether the use of cannabis
could have an opioid-reducing effect.18–20 Reports show a
beneficial effect of cannabis used together with opioids in
cancer pain relief21 and other chronic pain.18 Early US
ecological studies indicated that medical cannabis pre-
scribing was associated with significant reductions in opi-
oid prescribing,22–25 opening a discussion on the possible
role of medical cannabis in curbing the current US opioid
epidemic.26–28 A more recent ecological study, however,
questions these results and whether there is any benefit
for the opioid crises in the use of medical cannabis.29
Studies on individual level are rarer but have shown that
people who inject drugs and use cannabis use less opi-
oids30 and that pain patients can reduce their use of opi-
oids when they use medical cannabis.31,32 Other studies
find no positive effect,33 and some even suggest that can-
nabis use is a risk factor for developing problematic opi-
oid use.34,35 The latest review of the literature concluded
that there was low quality evidence for a modest effect of
adding cannabis concerning reduction or stopping opi-
oids.36 The need for further research is evident.
Medicinal cannabis products exist in several different
forms and formulations. In Europe, the most common
products are produced by Bedrocan®, who markets a
series of different products such as standardized cannabis
cigarettes or extracts, for example, in oils, and Sativex®, an
oro-mucosal spray containing standardized amounts of
Δ9-tetrahydrocannabinol (THC) and cannabinol (CBD).37
One prescription for Sativex® will in Norway provide up
to 4 weeks of Sativex® use, giving up to 12 doses of 2.5 mg
of THC and CBD, respectively, every day.38
Even if there are some studies of a possible opioid-
saving effect of cannabis on an individual level, these are
scarce and most of them are from the United States,
where there is high use of both opioids and cannabis.
The situation might be different in countries with lower
use of both.39 In the current study, we investigated
whether the introduction of the cannabis extract Sativex®
had any impact on the use of opioids on an individual
level in Norway. Such an investigation could shed light
on a possible opioid-reducing effect of cannabis.
1.1 | Aim
The study aimed to investigate the use of a cannabis
extract (Sativex®) among opioid users and to see whether
their use had any effect on use of opioids. More specifi-
cally, we wanted to investigate the following:
1. How many opioid users filled at least one prescription
for Sativex® during the observation period?
2. Compared to opioid users not using Sativex®, how did
their opioid use evolve from one year to the next?
3. Were there any differences between frequent and
occasional users of Sativex® concerning opioid use in
the follow-up year?
2 | METHODS
2.1 | Data source
All data for this study were drawn from the Norwegian
Prescription Database (NorPD). From 1 January 2004, all
pharmacies are obliged to submit data for all dispensed
drugs electronically to NorPD administered by the
Norwegian Institute of Public Health (www.norpd.no).
NorPD contains information on all drugs dispensed from
pharmacies, except for drugs administered at hospitals, in
nursing homes or outpatient clinics. In NorPD, drugs are
classified by the anatomic-therapeutic-chemical (ATC)
system of WHO.40
2.2 | Study population
All patients above 18 years of age who had filled at least
one prescription for an opioid (ATC codes N02A*) during
the 10 years from 1 January 2010 to 31 December 2019
were eligible for the study. The study population among
2 BRAMNESS ET AL.
these were those who received at least one prescription
for the cannabis-based medicine Sativex® (N02BG10).
2.3 | Data and analysis strategy
In the study, the parameters collected were patients’
unique identifiers (encrypted), gender, year of birth, year
of death, and date of dispensing, drug name, Nordic Arti-
cle Number, and defined daily dose (DDD). On the basis
of DDD, we calculated milligrams (mg) of oral morphine
equivalents (OMEQ).41 Sativex® has no defined DDD,42
but we studied those with any use of the drug and
defined those who filled zero to one prescription of
Sativex® within 364 days after the index prescription as
“occasional users,” and those filling two or more pre-
scriptions for Sativex® within 364 days after the index
prescription to “frequent users.”
2.4 | Pharmacoepidemiological analysis
We restricted our analysis to opioid users who had
received at least one prescription for opioids in the year
prior to filling their first prescription for Sativex® from
2011 to 2018, leaving 1 year to observe changes in opioid
use after the first prescription.
We compared the Sativex® users to a matched control
group of opioid users who did not receive any prescrip-
tions for Sativex® concerning their use of opioids in the
follow-up year. The control group of nonusers of Sativex®
was constructed as follows: For each Sativex® user, same-
sex nonusers born the same year, with roughly the same
opioid consumption, were eligible as controls. The
amount of OMEQ (mg) for the Sativex® user during the
365 days before the index date was compared with the
amount OMEQ for the control during the calendar year
of the Sativex® user’s index date. The control was chosen
randomly among those with an OMEQ amount within
1% of the Sativex® user’s OMEQ amount. If there were
no eligible controls within the calliper window of 1%,
the window was broadened in steps of 1% until it con-
tained at least one eligible control. For the control group,
we used the calendar year as the period for calculating
opioid use (index year), and the year after as follow-up
year. This was different from the dynamic years used for
the Sativex® users, where we looked at the 365 days
before and 0–364 days after their first prescription for
Sativex® as index- and follow-up year, respectively. Exact
date of dispensing was not available, only number of days
since an individual-specific, but unknown date in the
past, and hence we could not start the controls’ opioid
use period at the index date of the Sativex® users’ first
prescription. After the matching, we excluded individuals
who died within the calendar year after the index date.
For the controls, the time for possible death was exactly
1 year, but for the Sativex® users, it was on average
1.5 years because the “index date” could be anywhere
between 1 January and 31 December in the index year.
We compared the matched nonusers of Sativex® with
occasional users and frequent users on age, gender and
opioid use in the index year to check the matching, but
also to investigate differences between occasional and fre-
quent users. We compared the three groups on number
(share) of those stopping opioid use (“stoppers”), average
amount of opioids (in OMEQs) in the follow-up year, and
average change in the amount of opioid used from the
index year to the follow-up year (excluding the stoppers).
In a final linear regression analysis, we investigated
predictors of increase in OMEQ from the index year to
the follow-up year including both users of Sativex® and
nonusers (the control group). As explanatory variables,
we included age, gender, amount of opioid use in the
index year and the number of Sativex® prescriptions. For
the latter, we compared occasional and frequent Sativex®
users with nonusers. We also performed a sensitivity
analysis by investigating separately in a regression analy-
sis the effect of only one prescription for Sativex® and five
or more prescriptions for Sativex®.
2.5 | Statistical analyses
For age, we reported means and standard deviation (SD),
but for all other continuous variables (e.g., OMEQ), we
reported 25 and 75 percentiles as we know that drug use
among those receiving prescriptions is heavily skewed.43
For all categorical variables with less than 5 in the group,
values are given as “<5” due to regulations on anonymity
given by NorPD. For categorical variables, χ 2 test
was used to investigate significance; for age, Student’s
t-test was used, but for other continuous variables,
Mann–Whitney U-test or Kruskal–Wallis test were used.
We calculated the relative risk (RR) of stopping opioid
use from the index year to the follow-up year taking into
account gender, age, Sativex® use and amount of opioid
used in the index year. Lastly, we performed a regression
analysis with relative increase in opioid use from the
index year to the follow-up year in continuers as out-
come. Due to the asymmetric nature of this relative
increase, we used
Y ¼ X , X <1
21=X , X ≥ 1 where

¼mgOMEQ in follow-up year
mgOMEQ in index year:
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as dependent variable in the linear regression analysis.
The regression coefficients (β) with 95% confidence inter-
vals (95% CI) were reported. The analyses were per-
formed using the statistical program “R” version 4.0.3.
3 | RESULTS
Of the 2 210 149 patients who filled at least one prescrip-
tion for opioids during the 10-year period, only 1424
(0.06%) filled at least one prescription for Sativex®. Of
these Sativex® users, 882 (49.7%) received at least one
prescription for opioids in the year prior to starting
Sativex®. The number of incident users of Sativex® who
also received opioids the year before their prescription
rose from <5 in 2011 to 275 in 2019 (Figure 1). When
regarding any opioid use in the whole observation period,
the number receiving a prescription for Sativex® rose
from <5 in 2011 to 462 in 2019. For both measures, there
were peaks in 2013 and 2019.
The 607 opioid users who received a prescription for
Sativex® before 1 January 2019 (and were available for
1 year of follow-up) used a median of 2000-mg OMEQ
(IQ range 370–10 039 mg) not different from the matched
controls (p = 0.822) (Table 1). The number of deaths
were more than six times higher in Sativex® users than
in controls (p < 0.001). It should, however, be noted that
the controls had 365 days of follow-up with respect to
death, whereas the Sativex® users had between 365 and
730 days of follow-up, dependent on the date of the first
Sativex® prescription.
There was a trend that opioid users who became fre-
quent users of Sativex® more often stopped their opioid
use compared with controls and occasional users, but this
was not statistically significant (Table 2A). In the multi-
variate analysis, we found no significant predictors of
stopping opioid use, except that those who used the least
opioids more often stopped (p < 0.001).
In those who continued use of opioids, the use in the
follow-up year did not differ among all users of Sativex®
and the controls (p = 0.792; Table 1) nor did the median
change in opioid use differ (p = 0.813), but we found a
difference between occasional users and frequent users of
Sativex® (Table 1). The frequent users of Sativex® used
less opioids in the follow-up year compared with the
occasional users (p = 0.002; Table 1), and while the
median opioid use increased among the occasional users,
it decreased among the frequent user (p < 0.001).
To a large extent, the regression analysis confirmed
these results (Table 2B). Occasional users of Sativex®
who continued using opioids in the follow-up year,
increased their use of opioids (p < 0.001). This was oppo-
site among the frequent users of Sativex® who decreased
their use of opioids in the follow-up year compared with
nonusers of Sativex® (p = 0.008). In a sensitivity analysis
(data not shown in table), we also looked at those filling
only one prescription for Sativex® showing that these
individuals increased their use of opioids substantially
(p < 0.001), whereas those who filled five prescriptions or
more for Sativex® in the follow-up year, decreased their
opioid use substantially (p < 0.001). Those opioid users
who used more opioids in the index year decreased their
opioid use in the follow-up year.
4 | DISCUSSION
This study showed that very few opioid-using patients
filled a prescription for Sativex® during the observation
period. The few who did did not differ overall in their use
of opioids in the 1-year follow-up period starting on the
day of the first Sativex® prescription compared with con-
trols. However, when considering the number of Sativex®
prescriptions filled by the patients during the follow-up
year, another pattern occurred. Those filling one to two
prescriptions (occasional users) increased their use of opi-
oids in the follow-up year, whereas those who filled more
prescriptions (frequent users) reduced their opioid use
significantly, even to the point where we saw a dose–
response effect.
Many European countries have allowed the use of
cannabis-based medicine,37 including standardized can-
nabis extracts like Sativex®.44 Few studies have investi-
gated the prevalence of use in Europe, but European
F I GURE 1 Number of incident users of Sativex® per year
from 2011 to 2019 in Norway among users of opioids. Dotted line
indicates all users of opioids, while continuous line represents those
who received at least one prescription for opioids during the
365 days before their first prescription of Sativex®. Data from
NorPD
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levels of use are still thought to be quite low.45 Our study
confirms that the prevalence of use of the cannabis
extract Sativex® was very low in Norway in the observa-
tion period. This may have several explanations. There
could be scepticism concerning the effect of cannabis-
based medicines or little knowledge among health profes-
sionals.46 Another reason could be the high costs of
Sativex® not reimbursed in the Norwegian health care
system. After a peak in 2013, two years after its introduc-
tion to the Norwegian market, there was a drop in the
number of new Sativex® users. This early peak may
reflect a high expectation of the effect of the drug,47
maybe followed by a more realistic attitude. Since 2013,
there has been a steady increase in the number of users
to approximately 230 new users each year, a number that
spiked again in 2019, for unknown reasons.
In the present study, there was no general opioid-
saving effect of Sativex® in all those who tried the drug.
Our findings could thus be interpreted as contrary to
other researchers looking into cannabis-based medi-
cine.22–25,32,48,49 However, looking more closely at differ-
ent patterns of Sativex® use after the initial prescription,
we found that those filling only one or two prescriptions
in the follow-up year (occasional users) increased their
opioids use substantially, whereas there was a decrease
in those filling three or more prescriptions (frequent
users). The decrease was even more evident among those
filling five or more prescriptions. This strongly indicates
that some patients experience a beneficial effect from
their Sativex® use and continue this use, while reducing
their opioid use. Earlier research has not been able to
point to specific patients having a greater benefit of
medicinal cannabis.50 Our study was limited to pointing
out that some patients may experience an opioid-saving
effect of Sativex®, but the study cannot provide more
detail on who these patients were.
TAB L E 2 A Relative risk (RR) for stopping opioid use in the follow-up year for occasional and frequent users of Sativex® compared
with nonusers (unadjusted and adjusted estimates)
Ref
Unadjusted Adjusted
RR (95% CI) P value RR (95% CI) P value
Gender Male 0.98 (0.80; 1.20) .852 0.98 (0.82; 1.17) .811a
Age (per 10 years) Continuous 0.91 (0.84; 0.98) 1.00 (0.94; 1.07) .95a
Sativex® group
Occasional users Nonusers 0.98 (0.77; 1.25) .883 1.07 (0.87; 1.33) .510a
Frequent users Nonusers 1.14 (0.89; 1.47) .288 1.10 (0.88; 1.37) .401a
Amount of opioids (log2 of OMEQ) year
before first prescription of Sativex®
Continuous 0.76 (0.74; 0.78) <.001 0.76 (0.74; 0.78) <.001a
Note: Significant values are presented in bold.
aAdjusted for the other variables in the leftmost column.
TAB L E 2 B Linear regression for relative increase in opioid (in oral morphine equivalents; OMEQ) use from index year to follow-up
year in occasional and frequent users of Sativex® compared with nonusers (unadjusted and adjusted analysis)
Ref
Unadjusted Adjusted
Beta (95% CI) P value Beta (95% CI) P value
Gender Male .01 (0.06; 0.07) .874 .01 (0.05; 0.08) .678a
Age (per 10 years) Continuous .02 (0.00; 0.05) .086 .02 (0.01; 0.04) .232a
Sativex® group
Occasional users Nonusers .16 (0.08; 0.24) <.001 .16 (0.09; 0.24) <.001a
Frequent users Nonusers .09 (0.18; 0.00) .039 .09 (0.17; 0.00) .046a
Amount of opioids (log2 of OMEQ) year
before first prescription of Sativex®
Continuous .02 (0.03; 0.01) <.001 .02 (0.04; 0.01) <.001a
Note: Higher relative increase than in non-users gives a beta-coefficient above 0, while lower relative increase gives a beta-coefficient below 0. The dependent
variable in the regression is Y ¼ X , X <1
21=X , X ≥ 1

where X ¼ OMEQ follow-up yearOMEQ index year . Significant values are presented in bold.
aAdjusted for the other variables in the leftmost column.
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It is also noteworthy that the findings do not suggest
that cannabis-based medicines drives opioid use,34,35 an
effect we have previously observed for benzodiazepines.51
It must be noted that Norway is a country with moderate
use of opioids52 in addition to the very low use of canna-
bis as medicinal drug.
4.1 | Limitations
This study on whether starting to use the cannabis-based
medicine Sativex® resulted in a change in the use of opi-
oids has some limitations. The study covered only the use
of Sativex®, and not medical cannabis prescribed as stan-
dard joints, or “self-prescribed” medical cannabis. As it
was a prescription database study, we have no informa-
tion on other use of cannabis in the patients included,
like the use of medicinal cannabis imported by individ-
uals from abroad. Thus, many of the measures included
in previous studies on medical cannabis are not captured
by this study. Furthermore, the study only looked at opi-
oid consumption for the first year after starting treatment
with Sativex®. In chronic conditions, longer follow-up
times could be necessary, because of the long duration of
the condition. Also, we do not have information about
the indication for Sativex® use in the individual patient.
Thus, we cannot evaluate the effect in pain patients sepa-
rately, only study opioid usage in general. Lastly, even if
people filled prescriptions for drugs, we do not know if
the drugs were in fact taken (secondary noncompliance).
4.2 | Conclusion
This is one of a few studies investigating the impact of
medicinal cannabis use on individual level opioid use.
Very few opioid users used the cannabis extract Sativex®.
For opioid users in general, we found little evidence that
the use of a cannabis-based medicine reduced their use of
opioids. Some individuals, however, seemed to benefit
from continued use of Sativex® and were able to reduce
their use of opioids after having started with the drug.
Further studies should be performed to identify the char-
acteristics of individuals who may experience such bene-
ficial effects.
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